GEN Exclusives

More »

GEN News Highlights

More »
Jan 11, 2010

Ferrer InCode to Market BioTheranostics’ Cancer Classification Assay in Four Countries

  • Ferrer InCode negotiated an exclusive, three-year deal to commercialize bioTheranostics’ THEROS CancerTYPE ID® test in Spain, Portugal, Greece, and Venezuela. The assay is designed to help physicians identify the primary cancer in patients with metastatic disease of otherwise unknown origin.

    BioTheranostics is the cancer-focused molecular diagnostics subsidiary of bioMérieux. The company’s THEROS CancerTYPE ID works by measuring the expression of 92 cancer-related genes. BioTheranostics claims the test can help distinguish up to 39 different tumor types and 64 subtypes.

    Under terms of the commercialization deal, Ferrer InCode will market the assay in its designated territories, and BioTheranostics will carry out all sample testing in its laboratory in San Diego. During October 2009, the company signed a two-year commercialization agreement for THEROS CancerTYPE ID with Lab21 covering the U.K., Ireland, and Middle East countries.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »